The authors regret that the following errors occurred in following subsections. Changes can be found in italics below: 2.6. Pharmacokinetic (PK)assessment in humanized mice Further, all mice in ARV NPs and ARV solution treatment group, received subcutaneously (SubQ)TAF+FTC NPs and TAF+FTC along with elvitegavir (EVG)in solution (at 200 mg/kg each drug), respectively. However, EVG is not related to present study, has no drug-drug interactions and a complete PK study related to EVG has been previously published. Hence, EVG has not been discussed any further in the present article [2,3]. 2.9. Ethics statement Last sentence: All PK in vivo experiments (except the group of mice that received drugs in solution)were performed in accordance with Creighton University IACUC approved protocol (Protocol #0989). References AIDSinfo, Drug Interactions between Nucleoside Reverse Transcriptase Inhibitors and Other Drugs (Including Antiretroviral Agents). in: U.S.D.o.H.H. Services (Ed.), U.S. Department of Health & Human Services, Washington, DC, USA, 2018. P.K. Prathipati, S. Mandal, G. Pon, R. Vivekanandan, C.J. Destache, Pharmacokinetic and Tissue Distribution Profile of Long Acting Tenofovir Alafenamide and Elvitegravir Loaded Nanoparticles in Humanized Mice Model, Pharm Res, 34 (2017)2749-2755. S. Mandal, P.K. Prathipati, G. Kang, Y. Zhou, Z. Yuan, W. Fan, Q. Li, C.J. Destache, Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission, AIDS, 31 (2017)469-476. The authors would like to apologise for any inconvenience caused.
ASJC Scopus subject areas
- Pharmaceutical Science